PMID- 25533425
OWN - NLM
STAT- MEDLINE
DCOM- 20160127
LR  - 20211203
IS  - 1876-4738 (Electronic)
IS  - 0914-5087 (Linking)
VI  - 66
IP  - 1
DP  - 2015 Jul
TI  - Differential profile in inflammatory and mineral metabolism biomarkers in 
      patients with ischemic heart disease without classical coronary risk factors.
PG  - 22-7
LID - S0914-5087(14)00334-7 [pii]
LID - 10.1016/j.jjcc.2014.11.006 [doi]
AB  - BACKGROUND: Patients with coronary heart disease (CHD) without classical 
      cardiovascular risk factors (CRFs) are uncommon, and their profile has not been 
      thoroughly studied. In CHD patients, we have assessed the differences in several 
      biomarkers between those with and without CRF. METHODS: We studied 704 patients 
      with CHD, analyzing plasma levels of biomarkers related to inflammation, 
      thrombosis, renal damage, and heart failure: high-sensitivity C-reactive protein 
      (hs-CRP), monocyte chemoattractant protein-1 (MCP-1), galectin-3, N-terminal 
      fragment of brain natriuretic peptide (NT-pro-BNP), calcidiol (vitamin D 
      metabolite), fibroblast growth factor-23 (FGF-23), parathormone, and phosphate. 
      RESULTS: Twenty patients (2.8%) exhibited no CRFs. Clinical variables were well 
      balanced in both groups, with the logical exceptions of no use of antidiabetic 
      drugs, lower triglyceride and glucose, and higher high-density lipoprotein 
      cholesterol in no-CRF patients. No-CRF patients showed lower hs-CRP (2.574+/-3.120 
      vs. 4.554+/-9.786mg/L; p=0.018), MCP-1 (114.75+/-36.29 vs. 143.56+/-65.37pg/ml; 
      p=0.003), and FGF-23 (79.28+/-40.22 vs. 105.17+/-156.61RU/ml; p=0.024), and higher 
      calcidiol (23.66+/-9.12 vs. 19.49+/-8.18ng/ml; p=0.025) levels. At follow-up, 10.0% 
      vs. 11.0% patients experienced acute ischemic event, heart failure, or death in 
      the non-CRF and CRF groups, respectively (p=0.815, log-rank test). The limited 
      number of non-CRF patients may have influenced this finding. A Cox regression 
      analysis in the whole population showed that high calcidiol, and low MCP-1 and 
      FGF-23 plasma levels are associated with a better prognosis. CONCLUSIONS: CHD 
      patients without CRFs show a favorable biomarker profile in terms of inflammation 
      and mineral metabolism. Further studies are needed to investigate whether this 
      difference translates into a better prognosis.
CI  - Copyright (c) 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Pello, Ana Maria
AU  - Pello AM
AD  - Department of Cardiology, IIS-Fundacion Jimenez Diaz, Madrid, Spain.
FAU - Cristobal, Carmen
AU  - Cristobal C
AD  - Department of Cardiology, Hospital de Fuenlabrada, Fuenlabrada, Spain; Rey Juan 
      Carlos University, Alcorcon, Spain.
FAU - Tarin, Nieves
AU  - Tarin N
AD  - Department of Cardiology, Hospital Universitario de Mostoles, Mostoles, Spain.
FAU - Huelmos, Ana
AU  - Huelmos A
AD  - Department of Cardiology, Hospital Universitario Fundacion Alcorcon, Alcorcon, 
      Spain.
FAU - Acena, Alvaro
AU  - Acena A
AD  - Department of Cardiology, IIS-Fundacion Jimenez Diaz, Madrid, Spain.
FAU - Carda, Rocio
AU  - Carda R
AD  - Department of Cardiology, IIS-Fundacion Jimenez Diaz, Madrid, Spain.
FAU - Gonzalez-Casaus, Maria Luisa
AU  - Gonzalez-Casaus ML
AD  - Laboratory of Nephrology and Mineral Metabolism, Hospital Gomez-Ulla, Madrid, 
      Spain.
FAU - Alonso, Joaquin
AU  - Alonso J
AD  - Department of Cardiology, Hospital de Fuenlabrada, Fuenlabrada, Spain; Rey Juan 
      Carlos University, Alcorcon, Spain.
FAU - Lorenzo, Oscar
AU  - Lorenzo O
AD  - Laboratory of Vascular Pathology, IIS-Fundacion Jimenez Diaz, Madrid, Spain; 
      Autonoma University, Madrid, Spain.
FAU - Blanco-Colio, Luis
AU  - Blanco-Colio L
AD  - Laboratory of Vascular Pathology, IIS-Fundacion Jimenez Diaz, Madrid, Spain.
FAU - Martin-Ventura, Jose Luis
AU  - Martin-Ventura JL
AD  - Laboratory of Vascular Pathology, IIS-Fundacion Jimenez Diaz, Madrid, Spain; 
      Autonoma University, Madrid, Spain.
FAU - Franco Pelaez, Juan Antonio
AU  - Franco Pelaez JA
AD  - Department of Cardiology, IIS-Fundacion Jimenez Diaz, Madrid, Spain.
FAU - Mahillo-Fernandez, Ignacio
AU  - Mahillo-Fernandez I
AD  - Department of Epidemiology, IIS-Fundacion Jimenez Diaz, Madrid, Spain.
FAU - Farre, Jeronimo
AU  - Farre J
AD  - Department of Cardiology, IIS-Fundacion Jimenez Diaz, Madrid, Spain; Autonoma 
      University, Madrid, Spain.
FAU - Lopez-Bescos, Lorenzo
AU  - Lopez-Bescos L
AD  - Rey Juan Carlos University, Alcorcon, Spain.
FAU - Egido, Jesus
AU  - Egido J
AD  - Laboratory of Vascular Pathology, IIS-Fundacion Jimenez Diaz, Madrid, Spain; 
      Autonoma University, Madrid, Spain; Department of Nephrology, IIS-Fundacion 
      Jimenez Diaz, Madrid, Spain; CIBERDEM, Madrid, Spain.
FAU - Tunon, Jose
AU  - Tunon J
AD  - Department of Cardiology, IIS-Fundacion Jimenez Diaz, Madrid, Spain; Laboratory 
      of Vascular Pathology, IIS-Fundacion Jimenez Diaz, Madrid, Spain; Autonoma 
      University, Madrid, Spain. Electronic address: jtunon@secardiologia.es.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141219
PL  - Netherlands
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (FGF23 protein, human)
RN  - 0 (Galectin 3)
RN  - 0 (Lipoproteins, HDL)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Parathyroid Hormone)
RN  - 0 (Peptide Fragments)
RN  - 0 (Phosphates)
RN  - 0 (Triglycerides)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 62031-54-3 (Fibroblast Growth Factors)
RN  - 7Q7P4S7RRE (Fibroblast Growth Factor-23)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - P6YZ13C99Q (Calcifediol)
SB  - IM
MH  - Biomarkers/*blood
MH  - C-Reactive Protein/*metabolism
MH  - Calcifediol/blood
MH  - Chemokine CCL2/blood
MH  - Cholesterol/blood
MH  - Coronary Artery Disease/blood
MH  - Cross-Sectional Studies
MH  - Female
MH  - Fibroblast Growth Factor-23
MH  - Fibroblast Growth Factors/blood
MH  - Galectin 3/blood
MH  - Humans
MH  - Lipoproteins, HDL/blood
MH  - Lipoproteins, LDL/blood
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/*blood/etiology
MH  - Natriuretic Peptide, Brain/blood
MH  - Parathyroid Hormone/blood
MH  - Peptide Fragments/blood
MH  - Phosphates/blood
MH  - Prognosis
MH  - Risk Factors
MH  - Triglycerides/blood
OTO - NOTNLM
OT  - Atherosclerosis
OT  - Biomarkers
OT  - Cardiovascular risk factors
OT  - Fibroblast growth factor-23
OT  - Monocyte chemoattractant protein-1
EDAT- 2014/12/24 06:00
MHDA- 2016/01/28 06:00
CRDT- 2014/12/24 06:00
PHST- 2014/09/12 00:00 [received]
PHST- 2014/10/28 00:00 [revised]
PHST- 2014/11/19 00:00 [accepted]
PHST- 2014/12/24 06:00 [entrez]
PHST- 2014/12/24 06:00 [pubmed]
PHST- 2016/01/28 06:00 [medline]
AID - S0914-5087(14)00334-7 [pii]
AID - 10.1016/j.jjcc.2014.11.006 [doi]
PST - ppublish
SO  - J Cardiol. 2015 Jul;66(1):22-7. doi: 10.1016/j.jjcc.2014.11.006. Epub 2014 Dec 
      19.